Pay Attention to this Trade Activity as Nurix Therapeutics Inc. (NRIX) last week performance was -13.40%


Witnessing the stock’s movement on the chart, on November 23, 2022, Nurix Therapeutics Inc. (NASDAQ: NRIX) had a quiet start as it plunged -5.03% to $11.89. During the day, the stock rose to $12.83 and sunk to $11.86 before settling in for the price of $12.52 at the close. Taking a more long-term approach, NRIX posted a 52-week range of $7.52-$32.18.

Do You Own These 7 Inflation-Survival Stocks?

Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.

Click here to get your free copy of the report


Nevertheless, stock’s Earnings Per Share (EPS) this year is -145.60%. This publicly-traded company’s shares outstanding now amounts to $50.87 million, simultaneously with a float of $45.58 million. The organization now has a market capitalization sitting at $563.23 million. At the time of writing, stock’s 50-day Moving Average stood at $12.64, while the 200-day Moving Average is $13.63.

Nurix Therapeutics Inc. (NRIX) Ownership Facts and Figures

Nothing is more important than checking the behaviour of major investors towards the stock of the Biotechnology industry. Nurix Therapeutics Inc.’s current insider ownership accounts for 0.20%, in contrast to 94.40% institutional ownership. According to the most recent insider trade that took place on Oct 31, this organization’s EVP and COO sold 350 shares at the rate of 12.88, making the entire transaction reach 4,508 in total value, affecting insider ownership by 3,402. Preceding that transaction, on Oct 31, Company’s Chief Scientific Officer sold 1,165 for 12.88, making the whole transaction’s value amount to 15,006. This particular insider is now the holder of 21,214 in total.

Nurix Therapeutics Inc. (NRIX) Earnings and Revenue Records

As on 8/30/2022, Multinational firm has announced its last quarter scores, in which it reported -$0.9 earnings per share (EPS) for the period topping the consensus outlook (set at -$0.98) by $0.08. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.95 per share during the current fiscal year.

Nurix Therapeutics Inc.’s EPS decrease for this current 12-month fiscal period is -145.60% and is forecasted to reach -3.64 in the upcoming year.

Nurix Therapeutics Inc. (NASDAQ: NRIX) Trading Performance Indicators

Let’s observe the current performance indicators for Nurix Therapeutics Inc. (NRIX). It’s Quick Ratio in the last reported quarter now stands at 5.30. The Stock has managed to achieve an average true range (ATR) of 0.82. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 14.37.

In the same vein, NRIX’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -3.71, a figure that is expected to reach -0.79 in the next quarter, and analysts are predicting that it will be -3.64 at the market close of one year from today.

Technical Analysis of Nurix Therapeutics Inc. (NRIX)

Going through the that latest performance of [Nurix Therapeutics Inc., NRIX]. Its last 5-days volume of 0.29 million was inferior to the volume of 0.47 million it revealed a year ago. During the previous 9 days, stock’s Stochastic %D was recorded 10.43% While, its Average True Range was 0.84.


Please enter your comment!
Please enter your name here